Holen Sie sich die Stockscreener-App
3.65
0.27%
0.010
Schlusskurs vom Vortag:
$3.64
Offen:
$3.56
24-Stunden-Volumen:
1.31M
Relative Volume:
0.87
Marktkapitalisierung:
$332.80M
Einnahmen:
$58.36M
Nettoeinkommen (Verlust:
$-25.72M
KGV:
-8.1111
EPS:
-0.45
Netto-Cashflow:
$-24.91M
1W Leistung:
+1.11%
1M Leistung:
-22.91%
6M Leistung:
+46.00%
1J Leistung:
+95.19%
1-Tages-Spanne:
$3.52
$3.77
1-Wochen-Bereich:
$3.38
$3.915
52-Wochen-Spanne:
$1.84
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Firmenname
Aquestive Therapeutics Inc
Sektor
Telefon
908-941-1900
Adresse
30 TECHNOLOGY DRIVE, WARREN, NJ
Vergleichen Sie AQST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.65 | 332.80M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | Raymond James | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-04-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-03 | Eingeleitet | Lake Street | Buy |
| 2018-08-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-08-20 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of "Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST) - MarketBeat
Aquestive shares reiterated at Buy by analyst as FDA grants ODE to Libervant - Investing.com UK
Analysts Set Expectations for AQST FY2024 Earnings - Defense World
Wellington Management Group LLP Invests $922,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive receives FDA Orphan Drug Exclusivity for Libervant - MSN
Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment - Yahoo Finance
Aquestive Therapeutics Receives U.S. FDA Orphan Drug - GlobeNewswire
Cantor Fitzgerald Forecasts AQST FY2024 Earnings - MarketBeat
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25% - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by BNP Paribas Financial Markets - Defense World
Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Charles Schwab Investment Management Inc. Purchases 9,268 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics' SWOT analysis: stock poised for growth with innovative epinephrine delivery - Investing.com Canada
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside - Benzinga
Aquestive Therapeutics stock initiated at Overweight by Fitzgerald, eyes strong 2025 catalysts - Investing.com UK
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year - Yahoo Finance
Cantor Fitzgerald Initiates Coverage of Aquestive Therapeutics (AQST) with Overweight Recommendation - MSN
Aquestive Therapeutics (NASDAQ:AQST) shareholders have earned a 88% return over the last year - Simply Wall St
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth - Investing.com Nigeria
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth By Investing.com - Investing.com South Africa
Oral Thin Films Market Growth in Future Scope 2024-2031 | - openPR
Verition Fund Management LLC Takes $995,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics confirms FDA nod for Anaphylm trial By Investing.com - Investing.com Canada
Aquestive Therapeutics confirms FDA nod for Anaphylm trial - Investing.com
Aquestive Therapeutics Gains FDA Support for Anaphylm - TipRanks
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film - The Manila Times
Aquestive Therapeutics Announces Positive FDA Feedback and - GlobeNewswire
Aquestive's Oral Epinephrine Treatment Advances After Key FDA Feedback for NDA Filing - StockTitan
Aquestive therapeutics COO Jung Cassie sells $214 in stock By Investing.com - Investing.com Nigeria
Aquestive therapeutics COO Jung Cassie sells $214 in stock - Investing.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update - MarketBeat
GSA Capital Partners LLP Acquires 115,223 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc - GuruFocus.com
Chartwell Investment Partners LLC Buys New Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Aquestive Therapeutics to Present at Jefferies and Piper Sandler Healthcare Conferences | AQST Stock News - StockTitan
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
(AQST) On The My Stocks Page - Stock Traders Daily
HC Wainwright Issues Pessimistic Estimate for AQST Earnings - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for AQST Earnings - MarketBeat
Aquestive Therapeutics announces board changes - Investing.com India
Aquestive Therapeutics announces board changes By Investing.com - Investing.com UK
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2024 Earnings Call Transcript - Insider Monkey
Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aquestive Therapeutics Inc-Aktie (AQST) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 15 '24 |
Sale |
6.00 |
50,000 |
300,000 |
984,476 |
| Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 08 '24 |
Sale |
5.19 |
25,000 |
129,685 |
1,040,371 |
1.61%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):